Advertisement
Screener

Caribou Biosciences, Inc. (CRBU) Increase (Decrease) in Deferred Liabilities

2.8 / 5 stars · 68/120 Roast Me

Caribou Biosciences, Inc. Increase (Decrease) in Deferred Liabilities

Caribou Biosciences, Inc. (CRBU) reported Increase (Decrease) in Deferred Liabilities of -$548.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2026-03-05

  • Caribou Biosciences, Inc. increase (decrease) in deferred liabilities for the quarter ending 2020-12-31 was $57.00K.
  • Caribou Biosciences, Inc. increase (decrease) in deferred liabilities for the quarter ending 2020-09-30 was -$213.00K.
  • Caribou Biosciences, Inc. increase (decrease) in deferred liabilities for fiscal 2025 was -$548.00K.
  • Caribou Biosciences, Inc. increase (decrease) in deferred liabilities for fiscal 2024 was -$10.00K, a 105.65% decline from fiscal 2023.
  • Caribou Biosciences, Inc. increase (decrease) in deferred liabilities for fiscal 2023 was $177.00K.
  • Caribou Biosciences, Inc. increase (decrease) in deferred liabilities for fiscal 2022 was -$95.00K, a 129.60% decline from fiscal 2021.
Period endIncrease (Decrease) in Deferred Liabilities 3 monthIncrease (Decrease) in Deferred Liabilities 6 monthIncrease (Decrease) in Deferred Liabilities 9 monthIncrease (Decrease) in Deferred Liabilities 12 month
2025-12-31-$548.00K
10-K · filed 2026-03-05
2024-12-31-$10.00K
10-K · filed 2026-03-05
2023-12-31$177.00K
10-K · filed 2025-03-10
2022-12-31-$95.00K
10-K · filed 2024-03-11
2021-12-31$321.00K
10-K · filed 2023-03-09
2021-06-30$0.00
10-Q · filed 2021-09-02
2020-12-31$57.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21
-$156.00K
derived: sum of 2 quarters · filed 2022-03-21
-$495.00K
10-K · filed 2022-03-21
2020-09-30-$213.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
-$552.00K
10-Q · filed 2021-11-09
2020-06-30-$339.00K
10-Q · filed 2021-09-02
2019-12-31-$7.11M
10-K · filed 2022-03-21